[A retrospective controlled study of TACE-HAIC-targeted-immune quadruple therapy for intermediate and advanced-stage hepatocellular carcinoma].

医学 肝细胞癌 内科学 胃肠病学 阶段(地层学) 比例危险模型 联合疗法 对数秩检验 不利影响 肿瘤科 生存分析 入射(几何) 生物 光学 物理 古生物学
作者
L Li,Jiao He,Yuping Xie,X H Huang,Xiadi Weng,Xinting Pan,Yubin Jiao,Hou-bing Zheng,Luzhen Qiu,Wanping Guo
出处
期刊:PubMed 卷期号:30 (9): 939-946
标识
DOI:10.3760/cma.j.cn501113-20220823-00432
摘要

Objective: To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC)-targeted-immune quadruple therapy in patients with intermediate and advanced-stage hepatocellular carcinoma (HCC). Methods: 101 patients with intermediate and advanced stage HCC were enrolled according to the inclusion and exclusion criteria, and then they were divided into a combination group and a control group. Patients in the combination group was treated with TACE-HAIC-targeted-immune quadruple therapy, while the control group was only treated with TACE therapy. The overall survival (OS), progression-free survival (PFS), and treatment-related adverse reactions were statistically analyzed in the two groups of patients. Statistical analysis was carried out by t-test, χ2 test, rank sum test, Kaplan-Meier curve, log-rank test, Cox regression (or proportional hazards model) analysis according to different data. Results: The tumor objective response rate and disease control rate as evaluated by mRECIST 1.1 criteria in the combination group were 80% and 94%, respectively, which were significantly higher than those in the control group, 41.2% (P<0.001) and 74.5% (P=0.007). The OS and PFS of the combination group were 15.6 months [95%CI 11.3-NA ] and 8.8 months [95%CI 6.9-12.0], respectively, which were significantly better than the control group at 6.1 months [95%CI 5.3-6.6] (P<0.001) and 3.2 months [95%CI 3.0-3.6] (P<0.001). Gastric ulcer incidence was significantly higher in the combination group (9/50, 18%) than that in the control group (2/51, 3.9%) (P=0.023). Conclusion TACE-HAIC-targeted-immune quadruple therapy is a more effective treatment mode for intermediate and advanced-stage HCC than TACE alone, and attention should be paid to the monitoring of target immune-related adverse reactions.目的: 评价经导管动脉化疗栓塞术(TACE)-肝动脉灌注化疗(HAIC)-靶向-免疫四联治疗中晚期肝细胞癌(HCC)患者的疗效和安全性。 方法: 根据入排标准入组101例中晚期HCC患者,分为联合组和对照组。联合组患者行TACE-HAIC-靶向-免疫四联治疗,对照组患者仅接受TACE治疗。对2组患者的总生存期(OS)、无疾病进展生存期(PFS)、治疗相关的不良反应进行统计分析。据资料不同采用t检验、χ2检验、秩和检验、Kaplan-Meier曲线、对数秩检验、Cox回归分析或Cox比例风险模型分析进行统计学分析。 结果: 以mRECIST 1.1标准评估联合组肿瘤客观缓解率和疾病控制率分别为80%和94%,明显高于对照组的41.2%(P<0.001)和74.5%(P=0.007)。联合组的OS和PFS为15.6(95%CI 11.3~NA)个月和8.8(95%CI 6.9~12.0)个月,明显优于对照组的6.1(95%CI 5.3~6.6)个月(P<0.001)和3.2(95%CI 3.0~3.6)个月(P<0.001)。联合组胃溃疡发生率(9/50,18%)比对照组(2/51,3.9%)明显增加(P=0.023)。 结论: TACE-HAIC-靶向-免疫四联治疗对比单纯TACE治疗是一种更有效的中晚期HCC治疗方式,需注意对靶免治疗相关不良反应的监测。.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
fengw420发布了新的文献求助10
1秒前
偷喝汽水发布了新的文献求助10
2秒前
3秒前
3秒前
今后应助刘大宝采纳,获得10
3秒前
4秒前
Amiao应助Reuben采纳,获得10
4秒前
superspace发布了新的文献求助10
6秒前
tt完成签到,获得积分10
6秒前
小二郎应助缓慢的灵枫采纳,获得30
7秒前
333333发布了新的文献求助10
7秒前
早早发布了新的文献求助10
9秒前
你的文献完成签到,获得积分10
9秒前
coffeecoffee完成签到,获得积分20
9秒前
forever完成签到,获得积分10
9秒前
10秒前
uriah完成签到,获得积分20
10秒前
soda完成签到,获得积分10
11秒前
11秒前
酷波er应助太叔灭龙采纳,获得10
13秒前
13秒前
13秒前
uriah发布了新的文献求助200
14秒前
15秒前
刘大宝完成签到,获得积分10
15秒前
yayaya完成签到,获得积分10
15秒前
lalala发布了新的文献求助10
16秒前
毛豆应助科研通管家采纳,获得10
16秒前
16秒前
16秒前
丘比特应助科研通管家采纳,获得10
16秒前
科研通AI2S应助科研通管家采纳,获得10
16秒前
斯文败类应助希希子采纳,获得10
16秒前
完美世界应助科研通管家采纳,获得10
16秒前
16秒前
16秒前
刘大宝发布了新的文献求助10
17秒前
1234完成签到 ,获得积分10
17秒前
积极的万言完成签到,获得积分10
18秒前
19秒前
高分求助中
Spray / Wall-interaction Modelling by Dimensionless Data Analysis 2000
ALA生合成不全マウスでの糖代謝異常の分子機構解析 520
安全防范技术与工程 500
2024 Medicinal Chemistry Reviews 400
Dictionary of socialism 350
Geochemistry, 2nd Edition 地球化学经典教科书第二版 300
Idoxuridine 260
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3193422
求助须知:如何正确求助?哪些是违规求助? 2842415
关于积分的说明 8039135
捐赠科研通 2506377
什么是DOI,文献DOI怎么找? 1339098
科研通“疑难数据库(出版商)”最低求助积分说明 638616
邀请新用户注册赠送积分活动 607245